TrialSignal
Clinical trial intelligence report
A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01575873
Status
COMPLETED
Phase
PHASE3
Sponsor
Amgen
Executive brief
Investment-Ready Snapshot
This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01575873
Indication
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Modality
monoclonal antibody
Target
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Intervention
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.